Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 9476Neoplasms 6587Prostatic Neoplasms 4399Colorectal Neoplasms 3977Lung Neoplasms 3642Carcinoma, Non-Small-Cell Lung 3583Pancreatic Neoplasms 2478Carcinoma, Hepatocellular 2411Leukemia, Myeloid, Acute 2265Multiple Myeloma 2120Stomach Neoplasms 2108Neoplasm Metastasis 1911Head and Neck Neoplasms 1869Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1729Brain Neoplasms 1699Rectal Neoplasms 1676Melanoma 1654Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1485Esophageal Neoplasms 1311Glioblastoma 1307Lymphoma, Non-Hodgkin 1204Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

trifluridine tipiracil drug combination 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × First-line Treatment × Clear all
NCT05221775 2022-02-03

Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Tianjin Medical University Cancer Institute and Hospital

Phase 1 Unknown
18 enrolled
Gastrointestinal

First-line Treatment

NCT05077839 2021-10-25

TOBACO

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
184 enrolled
Gastrointestinal

First-line Treatment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡